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S U M M A R Y
The convergence between tuberculosis (TB) and diabetes mellitus (DM) will represent a major public
health challenge in the near future. DM increases the risk of developing TB by two to three times and also
increases the risk of TB treatment failure, relapse, and death. The global prevalence of DM is predicted to
rise signiﬁcantly in the next two decades, particularly in some of the low- and middle-income countries
with the highest TB burden. Migration may add further complexity to the effort to control the impact on
TB of the growing DM pandemic. Migration may increase the risk of DM, although the magnitude of this
association varies according to country of origin and ethnic group, due to genetic factors and lifestyle
differences. Migrants with TB may have an increased prevalence of DM compared to the native
population, and the risk of TB among persons with DM may be higher in migrants than in autochthonous
populations. Screening for DM among migrants, screening migrants with DM for active and latent TB, and
improving access to DM care, could contribute to mitigate the effects of DM on TB.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) is now the most common infectious disease
cause of death worldwide, and developing countries carry a large
burden of the 1.6 million deaths caused by TB every year.1 The
disease burden in developing countries due to non-communicable
diseases is also increasing and is no longer limited to communica-
ble diseases. Diabetes mellitus (DM) is a global epidemic disease
affecting both the developed and developing countries. Approxi-
mately 15% of TB patients have comorbidity with diabetes. The
convergence between the ongoing TB epidemic and some non-
communicable diseases such as diabetes will present a major
public health challenge in the near future.2 It has been estimated
that the global prevalence of diabetes will grow signiﬁcantly in the
coming decades, and this increase may be particularly marked in
some of the low-income and middle-income countries with the
highest burden of TB.3 Migration ﬂow from these countries has had
a major impact on the global dynamics of both diseases,4,5 and the
complex interaction among migration, TB, and diabetes needs to be
addressed in the context of the efforts to make progress towards
the ambitious goals of the post-2015 End TB Strategy.6
This review summarizes current knowledge on the biological
and epidemiological aspects of the association between TB and
diabetes and focuses on the interaction of international migration
with these two conditions. The available evidence on the impact of
migration on the DM–TB co-epidemics is also presented, and the
need for speciﬁc interventions to tackle this public health problem
is discussed.
The diabetes–tuberculosis co-epidemic
Although the link between type 2 diabetes and TB is well
recognized, it is only in the last decade that appreciation of its
relevance as a widespread public health problem has become the
focus of global attention. Four systematic reviews quantifying the
increased risk of developing TB among people with type 2 DM have
been published recently, and they show that DM increases the risk
of active TB by two to three times.7–10Moreover, the severity of DM
seems to be related to the magnitude of this risk: insulin-
dependence  as a marker of disease severity  predicts increased
TB risk,11,12 and poor glycaemic control has been identiﬁed as a risk
factor for TB.13
Epidemiological considerations
At the population level, a study by Goldhaber-Fiebert et al.,
performed between the 1990s and the early 2000s, showed that TB
prevalence and incidence were more likely to increase in countries
in which diabetes increased.14 An ecological longitudinal study
exploring the relationship between TB and diabetes globally in the
period 2000–2012 also found an increase in the prevalence of
diabetes with the incidence of TB, although this was limited to
countries with high diabetes prevalence rates ( > 7.6%), which were
primarily on the Asian Continent.15
The convergence of the diabetes and TB pandemics represents a
new phenomenon in the classic epidemiological transition
predicted by Omran in 1971,16 since the original theory did not
predict that elements of globalization and economic development
could so quickly generate an ‘age of degenerative diseases’ beforethe ‘age of receding pandemics’ was over. Due to the abundance of
calorie-dense/low-ﬁbre foods and the adoption of sedentary
lifestyles, the diabetes epidemic is rapidly growing, while the
spread of TB remains a global public health threat. The comorbidity
of TB and diabetes exempliﬁes an epidemiological transition where
chronic diseases occur simultaneously with infectious diseases,
“not simply in the same population, but in the same individual”.17
It was recently estimated that in 22 countries that carry 80% of
the global burden of TB, the proportion of cases attributable to
diabetes increased from 10% in 2010 to 15% in 2015%,6 and it was
stated that this fraction could grow further in the near future. In
fact, current predictions are that the prevalence of diabetes,
primarily type 2 diabetes, is set to rise beyond 592 million by
2035,2 and approximately 80% of these cases will be in low- and
middle-income countries, where the disease strikes at younger
ages and even lower body mass indexes,18 and where the
prevalence of TB is also high. By 2030, India, China, Indonesia,
Pakistan, and Brazil together are projected to have half of the
world’s people living with diabetes, and these countries are likely
to see the most signiﬁcant impacts of this co-epidemic in the near
future.14,19
Clinical considerations of diabetes–tuberculosis comorbidity
Patients with TB–diabetes appear to have poor TB treatment
outcomes. Those TB patients with poor blood sugar control have
increased rates of treatment failure, relapse, and death than those
with good glycaemic control. Diabetic patients with TB are also
more likely to develop multidrug-resistant TB (MDR-TB). Diabetes
modiﬁes the clinical presentation of pulmonary TB, is associated
with atypical radiological presentation,20 and increases the risk of
failure,20,21 death,22,23 reactivation, and relapse.13,20 Diabetes has
been found to be an independent risk factor for higher prevalence
or a greater severity of some symptoms, such as cough,
haemoptysis,14 and fever, and delayed sputum conversion.20,21
Data indicating higher bacillary burden in sputa of diabetic
patients are conﬂicting.24–26
Diabetes, immunosuppression, and increased susceptibility to
tuberculosis
It is well known that HIV infection increases the risk of
developing TB, and persons living with HIV have an increased risk
of metabolic syndromes, which in turn predispose them to
diabetes, possibly linked to the use of antiretroviral drugs.27–30
The relationship between HIV infection and the TB–diabetes
comorbidity, however, is still poorly explored, and more studies are
needed on this issue.
It is unclear whether diabetes increases susceptibility to initial
Mycobacterium tuberculosis infection or the risk of progression
from TB infection to active disease, but evidence for defects in
innate and adaptive immunity of patients with diabetes suggests
that this chronic disease can have an impact on both TB stages.31
Current ﬁndings on the underlying biology that promotes the TB–
diabetes association support an inefﬁcient innate immunity,
followed by a hyper-reactive cellular response to M. tuberculosis;
however, the contribution of these altered responses to TB
susceptibility or to the more adverse clinical outcomes of TB
patients with diabetes remains unclear.
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that found in diabetes, has been shown to have a negative impact
on immune function through the accumulation of advanced
glycation end-products that alter phagocyte function.32,33 In
particular, a reduction in M. tuberculosis phagocytosis, change in
the expression of genes that contribute to M. tuberculosis
containment34 or antigen presentation,35 and secretion of anti-
mycobacterial peptides36 have been described. Peripheral blood-
monocytes may also have defects in cell trafﬁcking due to higher
levels of CCR2 expression.37 This chemokine receptor plays an
important role in the migration of mononuclear cells to the lung, and
since the ligand of CCR2 (MCP1) is increased in the circulation of
patients with type 2 diabetes, these monocytes may be actively
retained in the circulation rather than trafﬁc to the site of disease.38
Regarding the adaptive immunity, higher levels of Th1 (inter-
feron gamma (IFN-g), interleukin (IL)-2) and Th17 (IL-17A, but not
IL-22) cytokines and a lower frequency of natural T-regulatory cells
(CD4+,CD25+,CD127) at baseline have been reported. However,
this is associated with higher IL-10 as well, suggesting that both
anti- and pro-inﬂammatory cytokines are up-regulated in TB
patients with diabetes compared to those with TB without
diabetes.38 In contrast, at the site of TB disease, in bronchoalveolar
lavage specimens from TB patients with diabetes, higher baseline
IL-10 but lower IFN-g has been found, suggesting that the lung
compartment may have a biased Th2 response in diabetes.39
Results from studies on induced IFN-g secretion have yielded
conﬂicting results.38–44 Some have shown that higher inducible
cytokine levels are correlated with poor glucose control (high
HbA1c).38,41
Autophagy is required for the effective control of intracellular
pathogens including M. tuberculosis,44–49 and is regulated by
mammalian target of rapamycin (mTOR) complex 1,50 a serine/
threonine kinase, and adenosine monophosphate-activated pro-
tein kinase (AMPK).51,52 Alterations of the autophagy network and
AMPK signalling have previously been associated with M.
tuberculosis virulence.53 It has been shown recently that the
AMPK-activating anti-diabetic drug metformin inhibits the intra-
cellular growth of M. tuberculosis, restricts disease immunopa-
thology, and enhances the efﬁcacy of conventional anti-TB drugs.54
In relation to metabolic disorders, it has been shown that M.
tuberculosis can also reside and persist in adipose tissues in a non-
replicating state, evading recognition by the host immune system
and forming a reservoir for possible reactivation.55
Malnutrition per se or due to diabetes may also alter the
function of the immune system. Malnutrition may lead to vitamin
deﬁciency. In particular, if vitamin D is decreased, several problems
related to the host defence against M. tuberculosis may arise, as this
is a potent modulator of innate immunity56,57 and an up-regulator
of autophagy in macrophages.57,58
Migration and diabetes
The number of international migrants or displaced people
worldwide continues to increase; it reached 244 million in 2015, an
increase from the 173 million reported in 2000. In 2015, India had
the largest ‘diaspora’ in the world (16 million), followed by Mexico,
the Russian Federation, China, Bangladesh, Pakistan, and
Ukraine.59 In addition, the unprecedented number of detections
of illegal border crossings occurring around and across the
Mediterranean in 2015 should be added to the ofﬁcial ﬁgures:
an estimated one million asylum seekers and migrants arrived at
European Union (EU) country borders declaring that they hailed
from Syria and Afghanistan.60
Several factors inﬂuence the link between migration status and
disease, including genetic factors and pre-migration history (socio-
economic level, lifestyle habits, exposure to infections), as well asthe quality of health care in the countries of destination and level of
integration of the migrant population.61 According to the
Organisation for Economic Co-operation and Development
(OECD)/EU,62 in 2012, most migrants perceived themselves to be
in overall good health, with no chronic illnesses, and no health-
related limitations; only those living in the Baltic countries or
Poland, where the immigrant populations are the oldest,
complained about their health status. Regarding unmet health
care needs, after adjusting for age, foreign-born people living in
Estonia, Sweden, Italy, Belgium, and Switzerland reported a higher
proportion of unmet medical needs than native-born people.
Two synergistic hypotheses have been formulated to explain
the reported lower levels of all-cause mortality and incidence of
some diseases such as stroke and cancer63 in many migrant
populations as compared to local-born populations:63–67 (1) the
‘salmon bias effect’, which assumes that out-migration is selective
for the sickest migrants, and (2) the ‘healthy migrant effect’, which
implies that in-migration is selective for the healthiest individua-
ls.68,69 Both are difﬁcult to examine due to the scarcity of data on
the health of populations in the countries of origin. As an
alternative, a few studies have evaluated the ‘healthy migrant
effect’ hypothesis by comparing health outcomes for migrant
groups and those born locally in immigration countries70,71 in the
USA, Netherlands,69 and Denmark,72 and have arrived at more
complex than expected explanatory models for selective migration
and for disease occurrence dynamics over time (including the role
of past exposures to infectious agents and the effects of trauma and
of the migration process itself).
On the other hand, a series of factors may expose migrants to a
higher risk of developing certain diseases after arrival in host
countries.4,61 Urbanization, mechanization, changes in nutrition
and lifestyle including physical inactivity, gene–environment
interactions, stress, and behaviours such as those experienced
by migrants originating from a poverty-ridden rural area in early
life and moving to an obesogenic urban environment in later life,
could confer an increased risk of obesity and diabetes among both
inter- and intra-country migrants in developed and developing
countries. The availability and abundance of calorie-dense/low-
ﬁbre foods and the adoption of sedentary lifestyles is associated
with increased risks of morbidity and mortality from chronic diet
and lifestyle-related diseases. This phenomenon could be espe-
cially relevant for recent migrants, while in the long term some
migrants may adopt healthier lifestyles.73
A number of studies have investigated the link between
migration and diabetes.4 For example, migrant Asian Indians
living in the UK were found to be more obese, to have higher blood
pressure, total cholesterol, and blood glucose levels, and to be more
insulin-resistant than their non-migrant siblings living in India.74
Migration itself seems to contribute to a further increase in truncal
subcutaneous abdominal adiposity, which has already been
reported among Asian Indians and South Asians.75,76 Lower indices
of obesity, insulin resistance, and type 2 diabetes have been
reported in the people of African origin residing in Nigeria than in
those of African origin living in the USA, while values in those living
in Jamaica were intermediate.77–79
A recent review by Montesi et al. collected and analysed the
evidence from the existing literature on diabetes and migration,
with special attention to host countries:61 in Europe, with a few
exceptions, the prevalence, incidence, and mortality rates80–82 for
diabetes were found to be much higher in migrants than in the
native people.4,83 Studies conducted in the UK have reported
differences in incidence and prevalence rates for migrants of both
South Asian origin (Afghanistan, Bhutan, Maldives, Nepal, and Sri
Lanka)84,85 and Sub-Saharan origin.86,87 Regarding the complica-
tions of diabetes, vascular complications and retinopathy were
found to be more common amongst some ethnic groups of
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according to the results reported by Choukem et al.,90 the
prevalence of diabetic nephropathy was higher in Africans living
in Cameroon than among Africans who had emigrated to France.
The diagnosis of diabetes was at a younger age than in natives and
than in non-migrants from the same country of birth.87, 90, 91 This
latter phenomenon may be explained by the selection bias of age at
migration, by late diagnosis of diabetes in the home country, or
may truly reﬂect a population trend of earlier onset of type
2 diabetes due to the rapid changes in lifestyle experienced by
migrants in the host country.92 Once diagnosed, diabetes care
seems to be of lower quality (higher likelihood of treatment with
oral drugs and longer length of hospital stay for migrants).91
Among persons migrating to the USA, the prevalence rates of both
diabetes and overweight were shown to vary according to region of
birth, ranging from 3.1% in Europe to 10.0% in the Indian
subcontinent. The three largest Asian American, native Hawaiian,
Paciﬁc Islander subgroups  from China, South Asia, and the
Philippines  are all at increased risk of developing diabetes,93 this
risk being higher than among non-Hispanic whites but lower than
that of African Americans and Latinos.94,95 In the Fremantle
Diabetes Study conducted in Australia, the prevalence in Asians
and the general population was similar, but the Asian patients were
younger, less obese, and less likely to be hypertensive.96while the
Melbourne Collaborative Cohort Study found more than three-fold
higher baseline prevalence and cumulative incidence of type
2 diabetes in migrants born in Greece or Italy than in individuals
born in Australia.97
In summary, the available evidence suggests that migration
may contribute to the onset of diabetes, and that persons migrating
from low- or middle-income countries to high-income countries
may have a higher prevalence of diabetes when compared to the
autochthonous population. However, signiﬁcant variations by
ethnic group have been recorded, and behavioural, lifestyle, and
genetic factors may contribute to this variability.Table 1
Diabetes mellitus prevalence in foreign-born and native patients with tuberculosis.
Author, year City, country Study period Type of study
Source
Results
Caraffa et al.
2016111
Rome, Italy 2007–12 Cross-sectional
Hospital-based
Medical records
 DM prevalence
 Foreign-born p
 DM prevalence
prevalence wa
prevalence 8
 DM prevalence
 DM prevalence
Demlow et al.
2015112
California,
USA
2010–12 Cross-sectional
Population-
based
Registry data
 DM prevalence
 Foreign-born p
 DM prevalence
 DM prevalence
 DM prevalence
Suwanpimolkul
et al. 2014113
San Francisco,
California,
USA
2005–12 Cross-sectional
retrospective
Hospital-based
Medical records
 DM prevalence
 Foreign born p
 DM prevalence
born 8.3%
 DM prevalence
 DM prevalence
Uchimura et al.
2013114
Japan 2007–10 Cross-sectional
Population-
based
Tuberculosis
registry
 DM prevalence
 Foreign-born p
 DM prevalence
 DM prevalence
 DM prevalence
DM, diabetes mellitus; TB, tuberculosis. ^Report of Tuberculosis in California, 2011, Ca
Program using data from Behavioural Risk Factor Surveillance System, 2001–2010, Na
Interview Survey 2009, and California Census Data, 2010Migration and tuberculosis
In most low-incidence countries, international migration
dynamics trends are known to contribute largely to TB
incidence.5,98–100 From 2000 to 2013, a disparity became evident
in high-income countries: while local-born cases remained static
or decreased, foreign-born cases decreased slowly or increased.5 In
2013, foreign-born cases in many high-income countries exceeded
50% of all TB cases,101–109with incidence rates 8.7 to 18.4 times
higher than among natives.
Migrants from high TB incidence countries could either have
active TB on arrival, or remotely-acquired latent TB infection (LTBI)
that reactivates post arrival due to socio-economic vulnerability
augmented by stressful migration conditions,109 or could acquire
TB through local transmission in the host country. The highest
incidence and risk of active TB following migration has been
reported for those migrating from Asia and Africa, for recent
migrants, refugees, and individuals with comorbidities (such as
HIV infection and diabetes).101–107,109
Addressing the special needs of migrants and cross-border
issues, and undertaking screening for active and latent TB in TB
contacts and selected high-risk groups, are among the priority
action areas deﬁned by the World Health Organization (WHO) in
2014 as part of the framework towards TB elimination in low-
incidence countries.109,110
Migrants as a vulnerable group for tuberculosis–diabetes
comorbidity
A review of published studies examining the impact of
migration on the association between diabetes and TB was
performed. The methods used to retrieve and select the articles
reviewed in this section are reported in Appendix A.
Four studies conducted in high-income–low TB burden
countries examined the prevalence of diabetes among patients
with TB by country of origin (Table 1). among TB patients overall: 63/971 (6.5%)
roportion in the study population: 723/971 (74.5%)
 among foreign-born patients: among 723 foreign-born TB patients, DM
s 5.4%; DM prevalence was 12.7% (8/63) among those born in countries with DM
%, 4.7% (31/660) among patients from countries with DM prevalence <8%
 among native patients: 24/248 (9.7%)
 in the general population: 5.13%
 among TB patients overall: 1463/6050 (24.2%)
roportion in the study population: 83.3%
 among foreign-born patients: 25.7%
 among native patients: 16.6%
 in the general population: 8.6% (California Diabetes Program data, 2011^^
 among TB patients overall: 126/791 (15.9%)
roportion in the study population: not reported
 among foreign-born patients: Philippines-born 31.9%, China-born 17.2%, Mexico-
 among native patients: 9.2%
 in the general population: 9.1% (California Diabetes Program data, 2009
 among TB patients overall: 12 694/96 689 (13.1%)
roportion in the study population: 3.8%
 among foreign-born patients: 3.4%
 among native patients: 13.5%
 in the general population: 5.1%
lifornia Department of Public Health, ^^Estimates provided by California Diabetes
tional Health and Nutrition Examination Survey 2007–2008, California S Hearth
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patients, 63 (6.5%) had diabetes.111 Diabetes prevalence was
highest among patients from countries with a diabetes prevalence
8% (8/63, 12.7%), followed by those born in Italy (24/248, 9.7%)
and by foreign-born patients from countries with a diabetes
prevalence <8%. Almost 70% of foreign-born TB–diabetes patients
were from a country with a diabetes prevalence 8%, most
frequently from Africa (Egypt, Libya, and Morocco) and Asia (India).
Foreign-born patients were younger than those born in Italy. In the
multivariable analysis, after adjusting for age, foreign-born
patients from countries with a diabetes prevalence <8% were
three times more likely to have diabetes, and patients from
countries with a diabetes prevalence 8% were six times more
likely to have diabetes, compared to those born in Italy.
Demlow et al. reported that during 2010–2012, 1463 (24%) of
the 6050 active TB cases diagnosed in California had diabetes.112
Among foreign-born patients, who constituted more than 80% of
this patient population, 31% had diabetes compared to 15% among
those born in the USA or Canada. In the multivariable analysis
among both TB cases and the general adult population in
California, persons with diabetes were more likely to be male,
older than 44 years, and foreign-born.
The impact of diabetes on TB in the USA and foreign-born
populations in San Francisco, California was also studied between
2005 and 2012 by Suwanpimolkul et al.113 The prevalence of
diabetes among 791 patients with TB was 15.9% (9.2% among those
born in the USA and 17.8% among those foreign born) and was
higher for individuals born in the Philippines (31.9%) than for those
born in China (17.2%) or Mexico (8.3%). In the multivariable
analysis, being born in the Philippines was signiﬁcantly associated
with diabetes.
In contrast to the previously mentioned studies, an analysis of
Japanese TB surveillance data of all cases registered between 2007
and 2010 found a prevalence of diabetes among foreign TB patients
of 3.4% compared to 13.4% among Japanese patients. However,
foreigners represented less than 5% in that study, and they were
younger than the Japanese patients.115 Taken together, these
studies suggest that the prevalence of diabetes among patients
with TB reﬂects the prevalence of diabetes in the ethnic groups of
origin, while these studies do not allow a direct assessment of the
effect of migration on the association between diabetes and TB.
Three studies examined the risk of TB in patients with diabetes
by country of origin (Table 2). In a case–control study conducted in
Denmark, in which the prevalence of diabetes was assessed inTable 2
Tuberculosis incidence in foreign-born and native patients with diabetes mellitus.
Author,
year
City,
country
Study period Type of study
Source
Results
Demlow
et al.
2015112
California,
USA
2010–12 Cross-sectional
Population-based
Survey aggregated data
 TB incid
 Foreign
 TB incid
 TB incid
 General
2011)
 Relative
 Number
DM, 152
Leegaard
et al.
2011115
Northern
Denmark
1980–2008 Case–control
Population-based
Danish National Registry of
Patients and Residents Registry
 DM pre
 Foreign
 Adjuste
TB amo
immigr
Marks
2011117
USA 2000–05 Cross-sectional
Population-based
Survey individual data
 Adjuste
non-His
TB, tuberculosis; DM, diabetes mellitus; OR, odds ratio; CI, conﬁdence interval; aOR, adpatients with TB and in matched population controls, a low risk
increase for TB associated with diabetes was recorded overall (odds
ratio 1.18, 95% conﬁdence interval 0.96–1.45), with a similar risk for
migrants (odds ratio 1.23, 95% conﬁdence interval 0.78–1.93). The
authors noted, however, that the probability of having diabetes
detected may have been lower in migrants with TB than in Danes
because of a short stay in the host country or different health care-
seeking behaviour.115
The incidence of TB among patients with diabetes by birth
location was assessed in the retrospective population-based study
conducted in California already mentioned above.112 The overall
incidence of TB among persons without diabetes was 6.0 per 100
000 per year compared to 21.0 per 100 000 per year among persons
with diabetes; among these persons, foreign-born persons had an
overall TB rate of 142/100 000, almost 12 times greater than among
USA or Canadian-born persons (12/100 000). The highest TB
incidence rates were recorded among persons born in Southeast
Asia and the Paciﬁc Islands, with rates in the different age strata
ranging from 117 to 239 per 100 000. The overall relative risk of TB
for persons with diabetes was 3.5, and was relatively consistent for
different locations of birth.
The heterogeneity of risk by ethnic group recorded in California
is consistent with the results of the epidemiological model
constructed using data on the incidence of TB, the prevalence of
diabetes, the population structure for 2005, and the age-speciﬁc
relative risk of TB associated with diabetes from a large cohort
study in England.116 In this model, the estimated population
attributable factor of diabetes for pulmonary TB was highest for
Asian men (16.6%) and women (14.2%). Lower ﬁgures were
recorded for white persons (6.9% in men and 8.2% in women)
and black persons (7.4% in men and 8.9% in women) despite a
higher prevalence of diabetes in the black population, reﬂecting a
much younger mean age of pulmonary TB in the black population.
Finally, history of TB among diabetic patients was analysed
using data collected in the context of the US National Health
Interview Survey (NHIS) between 2000 and 2005.117 Fourteen
percent of individuals in the survey were foreign-born, and among
them, the reported prevalence of diabetes rose progressively in
relation to years of residence in the USA. In fact diabetics who were
foreign-born and non-Hispanic had an odds ratio for TB of 2.2 (99%
conﬁdence interval 1.6–3.2) compared to those who were USA-
born and non-Hispanic, and USA-born Hispanics had an odds ratio
for TB of 2.1 (99% conﬁdence interval 1.4–3.2) compared to those
who were foreign-born and non-Hispanic.ence rate among DM patients overall: 21/100 000
-born proportion in the study population: 60.5%
ence rate among foreign-born patients: 142/100 000 foreign-born patients
ence rate among native patients: 12/100 000 USA/Canadian-born
 population TB incidence rate: 5.9/100 000 (report on tuberculosis in California,
 risk for TB among persons with DM: 3.5 (95% CI 3.3–3.7)
 of persons needed to be screened: 7930 among all adults, 2740 among adults with
6 among all foreign-born patients, and 596 among foreign-born patients with DM
valence overall: 156/2950 (5.3%)
-born proportion in the study population: 28.6%
d OR for TB among subjects with DM: 1.18 (95% CI 0.96–1.45); the adjusted ORs for
ng DB cases were similar among native Danes (1.17, 95% CI 0.93–1.46) and
ants (1.23, 95% CI 0.78–1.93)
d OR for history of TB was 1.4 (99% CI 1.0–2.0), controlling for being foreign-born
panic (aOR 2.2, 99% CI 1.6–3.2), USA-born Hispanic (aOR 2.1, 99% CI 1.4–3.2)
justed odds ratio.
50 E. Girardi et al. / International Journal of Infectious Diseases 56 (2017) 45–53These studies suggest that the relative risk of developing TB is
similar for migrants and autochthonous populations in countries
with a low TB burden. On the other hand, given the increased
incidence of TB for those migrating from high-incidence countries,
the absolute increased risk associated with diabetes is much higher
for some groups of migrants. In addition, the fraction of TB cases
attributable to diabetes may be considerable in some ethnic groups
with a high prevalence of diabetes and TB infection.
Conclusions and policy implications
Migration may add further complexity to the efforts to control
the growing diabetes pandemic. Available data suggest that in
most instances persons migrating from low- and middle-income
countries have a higher prevalence of diabetes compared to the
native population, and also somehow higher than in persons from
the same population who remain in the country of origin. However,
signiﬁcant heterogeneity is observed in the magnitude of
association between migration and diabetes according to the
country of origin and ethnic group, and this may reﬂect genetic
factors and diet and lifestyle differences. The interaction between
diabetes and migration may in turn have an impact on
interventions aimed at reducing the impact of diabetes on the
burden of TB.
The potential impact of interventions related to the co-
epidemic on the overall trends of TB burden appears to be very
high.
A model simulation assessed the impact of diabetes prevention
on TB incidence in 13 countries that carry over 60% of the global TB
burden and with a low-level HIV epidemic.118 According to this
model, if diabetes prevalence continues to grow in the next 20
years, this will determine a reversal in the present trend of a
decrease in TB incidence. In contrast, preventing the rise in TB
incidence would determine an acceleration of the declining trend
in TB, and a policy that could determine a reduction in diabetes
prevalence would result in 7.8 million cases of TB and 1.5 million
deaths being avoided over the next two decades.
In another simulation, Odone et al. analysed the potential effect
of a combination of improved prevention and care of diabetes with
a reduction in undernutrition as a tool to decrease the TB
burden.119 In the baseline scenario, the projected 21% global
increase in diabetes prevalence by 2035 would be associated with a
global TB incidence 3% higher compared with the present ﬁgures.
On the other hand, implementing interventions that could
decrease the effect of diabetes on the risk of TB through the
treatment of LTBI and better glucose control would result in the
model with a 15% lower incidence of TB in 2035 compared with the
baseline scenario.
The current WHO End TB Strategy is based on three pillars:
integrated patient-centred TB care and prevention, bold policies,
and supportive systems. Interventions on the association between
TB and diabetes are recommended for each one of these areas.6
These interventions include screening for active TB among patients
with diabetes in high TB burden settings and screening for diabetes
among patients with TB; screening for and treating LTBI in
diabetics at high risk of disease progression, ensuring access to
health care including diabetes care; and operational research on
TB–diabetes common activities.
What is the speciﬁc relevance of these interventions for
migrants?
The yield of screening for active TB among diabetics varies
greatly according to the tools used and the background TB
prevalence, and the effectiveness of this intervention may be
unacceptably low in low TB burden countries.6,7 Nonetheless, evenin these countries, screening programmes targeted at migrants
with diabetes from ethnic groups disproportionately affected by
diabetes and TB may eventually prove effective.
Screening for and treatment of LTBI in diabetics is not generally
recommended;120 however, similarly to screening for active TB,
this intervention should be evaluated in some groups of migrants.
For example, the study conducted in California mentioned
previously suggested that almost 10 000 USA-born adults with
diabetes would have to be screened for TB infection to prevent one
case of TB, while the number that would need to be screened
would be around 300 for diabetics born in Southeast Asia/Paciﬁc
Islands.112 Screening for TB infection is recommended for persons
migrating to low TB incidence countries from countries with a high
TB incidence, which is usually deﬁned as a rate above 100 per 100
000; however, this threshold should be re-evaluated, and possibly
lowered, when deciding whether migrants with diabetes should be
screened.
An obvious prerequisite for the above-mentioned interventions
is adequate identiﬁcation of diabetes in migrants. Data on the
prevalence of undiagnosed diabetes among migrants are sparse;
however this phenomenon is likely to be relevant. It has been
estimated that globally, 45.8% or 174.8 million of all diabetes cases
in adults are undiagnosed, and this proportion may be as high as
75% in some African countries.121An estimated 83.8% of all cases of
undiagnosed diabetes are in low- and middle-income countries
from which the vast majority of migrants originate. In a study
conducted on the USA–Mexico border, Mexicans (43.8%) andMex-
ican immigrants (39.0%) with diabetes were signiﬁcantly more likely
to be undiagnosed than were USA-born Hispanics (15.0%) or non-
Hispanic whites (6.6%).122 In another study, 58.5% of Mexican
immigrants with diabetes in their ﬁrst 4 years in the USA were
undiagnosed, compared to 29.5% of those who had migrated a longer
time ago.123 In the UK, the risk of having undiagnosed diabetes was
found to be two times higher among adults originating from Asian
countries than among white Europeans.124 In Italy, diabetes was
more frequently diagnosed at the time of TB diagnosis in the foreign-
born than in Italian patients (28.2% vs. 16.7%).111 This evidence
suggests that screening for diabetes should be considered an
important component of health services to be provided to migrants.
There is also evidence that in Europe, migrants with diabetes
have a higher incidence of complications and lower use of anti-
diabetic drugs compared to the autochthonous populations,91,125
suggesting the need to improve access to high quality diabetes care
for migrants.
In conclusion, the screening of diabetics for active TB and for TB
infection, screening for diabetes among migrants,126–128 and
improved access to diabetes care, could contribute to mitigate
the effect of diabetes on TB among migrants. Operational research
on the implementation of these interventions and the evaluation of
their effectiveness in different settings and in different migrant
populations are badly needed.
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